There is an urgent need to identify novel therapies for childhood cancers. Neuroblastoma is
the most common pediatric solid tumor, and accounts for~ 15% of childhood cancer‐related …

Despite being the subject of extensive research and clinical trials, neuroblastoma remains a
major therapeutic challenge in pediatric oncology. The p53 protein is a central safeguard …

Neuroblastoma has a low mutation rate for the p53 gene. Alternative ways of p53
inactivation have been proposed in neuroblastoma, such as abnormal cytoplasmic …

Tumor suppressor p53 mutations are associated with more than 50% of cancers.
Aggregation and amyloid formation of p53 is also implicated in cancer pathogenesis, but …

Mutations in the p53 tumor suppressor are frequent causes of cancer. Because p53
aggregates appear in some tumor cells, it has been suggested that p53 could also cause …

Simple Summary Preclinical analyses identified APR-246 as a potent treatment option for
neuroblastoma. However, a specific mode of action, sufficient biomarkers and promising …

Simple Summary The tumor suppressor gene TP53 is found mutated in around half of
human cancers. The accumulation of the mutant p53 protein in the form of aggregates in …

Dysregulation of nucleocytoplasmic shuttling is commonly observed in cancers and
emerging as a cancer hallmark for the development of anticancer therapeutic strategies …

The tumor suppressor p53 protein controls cell cycle and plays a vital role in preserving
DNA integrity. p53 is activated by varied stress signals and the distribution of p53 between …

Autism spectrum disorder (ASD) is a highly prevalent neurodevelopmental disorder
characterized by developmental delay, social deficits, and restricted, repetitive behaviors …